26 April 2018  
EMA/258941/2018  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Perjeta 
pertuzumab 
On 26 April 2018, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Perjeta. The marketing authorisation holder for this medicinal product is Roche Registration GmbH. 
The CHMP adopted an extension to the existing indication as follows2: 
“Early breast cancer 
Perjeta is indicated for use in combination with trastuzumab and chemotherapy in: 
• 
• 
the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, 
inflammatory, or early stage breast cancer at high risk of recurrence (see section 5.1) 
the adjuvant treatment of adult patients with HER2-positive early breast cancer at high 
risk of recurrence (see section 5.1) 
Neoadjuvant treatment of breast cancer 
Perjeta is indicated for use in combination with trastuzumab and chemotherapy for the neoadjuvant 
treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast 
cancer at high risk of recurrence (see section 5.1)” 
Metastatic breast cancer 
Perjeta is indicated for use in combination with trastuzumab and docetaxel in adult patients with 
HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received 
previous anti-HER2 therapy or chemotherapy for their metastatic disease.” 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold, removed text as strikethrough 
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom 
Telephone  +44 (0)20 3660 6000  Facsimile +44 (0)20 3660 5520 
Send a question via our website www.ema.europa.eu/contact 
An agency of the European Union   
© European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 
 
  
 
 
 
  
                                                
